Scinai Immunotherapeutics Ltd.
SCNI
$1.13
-$0.14-11.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2023 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | 7.31% | -174.99% | -174.99% | 182.59% |
| Total Depreciation and Amortization | 0.00% | -29.46% | -42.07% | -42.07% | -1.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -15.83% | -159.75% | -159.75% | 3.69% |
| Change in Net Operating Assets | 0.00% | -41.89% | 190.51% | 190.51% | -328.40% |
| Cash from Operations | 0.00% | -19.66% | 44.87% | 44.87% | 22.74% |
| Capital Expenditure | 0.00% | -- | -1,070.00% | -1,070.00% | 94.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -- | -1,070.00% | -1,070.00% | 94.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00% | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00% | -60.48% | -100.00% | -100.00% | -- |
| Foreign Exchange rate Adjustments | 0.00% | 950.00% | -300.00% | -300.00% | 117.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | -152.05% | -28.20% | -28.20% | 65.12% |